As of 2024-12-14, the Relative Valuation of Blueprint Medicines Corp (BPMC) is (36.08) USD. This relative valuation is based on P/E multiples. With the latest stock price at 93.19 USD, the upside of Blueprint Medicines Corp based on Relative Valuation is -138.7%.
The range of the Relative Valuation is (35.68) - (38.74) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 15.9x - 31.0x | 17.3x |
| Forward P/E multiples | 17.7x - 19.2x | 18.5x |
| Fair Price | (35.68) - (38.74) | (36.08) |
| Upside | -138.3% - -141.6% | -138.7% |
| Date | P/E |
| 2024-12-13 | -46.23 |
| 2024-12-12 | -45.93 |
| 2024-12-11 | -46.87 |
| 2024-12-10 | -47.33 |
| 2024-12-09 | -46.92 |
| 2024-12-06 | -47.61 |
| 2024-12-05 | -47.17 |
| 2024-12-04 | -47.89 |
| 2024-12-03 | -47.89 |
| 2024-12-02 | -48.43 |
| 2024-11-29 | -47.82 |
| 2024-11-27 | -47.18 |
| 2024-11-26 | -46.95 |
| 2024-11-25 | -46.57 |
| 2024-11-22 | -46.71 |
| 2024-11-21 | -47.94 |
| 2024-11-20 | -47.04 |
| 2024-11-19 | -46.93 |
| 2024-11-18 | -44.74 |
| 2024-11-15 | -44.00 |
| 2024-11-14 | -47.46 |
| 2024-11-13 | -48.07 |
| 2024-11-12 | -47.94 |
| 2024-11-11 | -49.55 |
| 2024-11-08 | -50.03 |
| 2024-11-07 | -50.30 |
| 2024-11-06 | -49.43 |
| 2024-11-05 | -48.40 |
| 2024-11-04 | -45.58 |
| 2024-11-01 | -45.00 |
| 2024-10-31 | -43.42 |
| 2024-10-30 | -44.28 |
| 2024-10-29 | -41.38 |
| 2024-10-28 | -41.07 |
| 2024-10-25 | -40.92 |
| 2024-10-24 | -41.22 |
| 2024-10-23 | -41.87 |
| 2024-10-22 | -42.90 |
| 2024-10-21 | -42.47 |
| 2024-10-18 | -42.67 |
| 2024-10-17 | -42.67 |
| 2024-10-16 | -44.32 |
| 2024-10-15 | -44.25 |
| 2024-10-14 | -43.98 |
| 2024-10-11 | -44.06 |
| 2024-10-10 | -43.15 |
| 2024-10-09 | -43.45 |
| 2024-10-08 | -43.40 |
| 2024-10-07 | -44.31 |
| 2024-10-04 | -43.96 |